Warning: The NCBI web site requires JavaScript to function. more...
The scope of costs in alcohol studies: Cost-of-illness studies differ from economic evaluations.
van Gils PF, Hamberg-van Reenen HH, van den Berg M, Tariq L, de Wit GA.
Cost Eff Resour Alloc. 2010 Jul 6;8:15.
Related citations
Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.
Roy S, Madhavan SS.
Pharmacoeconomics. 2008;26(4):281-96. Review.
The economic costs of alcohol abuse in Ontario.
Xie X, Rehm J, Single E, Robson L, Paul J.
Pharmacol Res. 1998 Mar;37(3):241-9.
Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.
Krol M, Papenburg J, Koopmanschap M, Brouwer W.
Pharmacoeconomics. 2011 Jul;29(7):601-19. doi: 10.2165/11539970-000000000-00000. Review.
Economic evaluations and randomized trials in spinal disorders: principles and methods.
Korthals-de Bos I, van Tulder M, van Dieten H, Bouter L.
Spine (Phila Pa 1976). 2004 Feb 15;29(4):442-8.
Depression: cost-of-illness studies in the international literature, a review.
Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F.
J Ment Health Policy Econ. 2000 Mar 1;3(1):3-10.
Economic evaluation and mental health: sparse past. fertile future?
Knapp M.
J Ment Health Policy Econ. 1999 Dec 1;2(4):163-167.
Costs and effectiveness of substance abuse treatments for homeless persons.
Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K.
J Ment Health Policy Econ. 2002 Mar;5(1):33-42.
Economic effects of clinical pharmacy interventions: a literature review.
De Rijdt T, Willems L, Simoens S.
Am J Health Syst Pharm. 2008 Jun 15;65(12):1161-72. Review.
Home treatment for mental health problems: a systematic review.
Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, Wright C.
Health Technol Assess. 2001;5(15):1-139. Review.
Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.
Pharmacoeconomics. 2008;26(1):57-73.
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
Krauth C, Jalilvand N, Welte T, Busse R.
Pharmacoeconomics. 2003;21(14):1001-24. Review.
The economic impact of alcohol consumption: a systematic review.
Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Chaikledkaew U.
Subst Abuse Treat Prev Policy. 2009 Nov 25;4:20. Review.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Methodological assessment of economic evaluations of alcohol treatment: what is missing?
Barbosa C, Godfrey C, Parrott S.
Alcohol Alcohol. 2010 Jan-Feb;45(1):53-63. Epub 2009 Oct 6. Review.
Two methods of estimating health costs linked to alcoholism in France (with a note on social costs).
Reynaud M, Gaudin-Colombel AF, Le Pen C.
Alcohol Alcohol. 2001 Jan-Feb;36(1):89-95.
Societal costs of underage drinking.
Miller TR, Levy DT, Spicer RS, Taylor DM.
J Stud Alcohol. 2006 Jul;67(4):519-28.
Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse.
Holder HD.
J Ment Health Policy Econ. 1998 Mar;1(1):23-29.
The social costs of alcohol abuse in New Zealand.
Devlin NJ, Scuffham PA, Bunt LJ.
Addiction. 1997 Nov;92(11):1491-505.
Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
Bereza BG, Machado M, Einarson TR.
Clin Ther. 2009 Jun;31(6):1279-308. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on